Butyric acid is an important organic acid with diverse applications; however, microbial production is hampered by the scarcity of acid-tolerant hosts. Here, we established a cytosolic reverse β-oxidation pathway in the acid-tolerant non-conventional yeast Pichia kudriavzevii E1 for butyric acid production. Strategies to enhance cytosolic acetyl-CoA availability were evaluated, including glyoxylate cycle disruption, acetyl-CoA synthetase overexpression, mobilization of peroxisomal acetyl units, and cytosolic expression of the pyruvate dehydrogenase complex. Cytosolic expression of the pyruvate dehydrogenase complex increased butyric acid production 1.7-fold, highlighting the importance of acetyl-CoA compartmentalization. Evaluation of pathway enzymes identified trans-enoyl-CoA reductase (Ter) as a potential rate-limiting enzyme. A previously uncharacterized Ter enzyme, designated LpTer, was identified from a strong-aroma Baijiu pit-mud metagenome. Optimizing LpTer copy number and cytosolic NADH utilization increased the butyric acid titer to 339.07 ± 8.30 mg/L, representing an approximately 68-fold improvement over the initial strain. This study represents the first systematic engineering of the acid-tolerant yeast P. kudriavzevii for de novo butyric acid production without pH adjustment through pathway optimization and enzyme mining.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: